Disease · EFO_0010134
kidney transplant
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. kidney transplant. Diseases, record EFO_0010134. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0010134
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- kidney transplant
- Open Targets ID
- EFO_0010134
- Highest stage of its drugs
- Approval, for 6 of its 45 drugs, from EMA Human Drugs
Source Open Targets
Drugs45
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TACROLIMUS | CHEMBL3989887 | Small molecule | Approval | EMA Human Drugs | 36 | 35 | 35 | Drugs and targets |
| SIROLIMUS | CHEMBL413 | Small molecule | Approval | EMA Human Drugs | 8 | 7 | 7 | Drugs and targets |
| BASILIXIMAB | CHEMBL1201439 | Antibody | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| IMLIFIDASE | CHEMBL4297981 | Enzyme | Approval | EMA Human Drugs | 5 | 3 | 3 | Drugs and targets |
| DACLIZUMAB | CHEMBL1201605 | Antibody | Approval | EMA Human Drugs, at withdrawal | 3 | 2 | 2 | Drugs and targets |
| BELATACEPT | CHEMBL1742990 | Protein | Approval | EMA Human Drugs | 2 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| EVEROLIMUS | CHEMBL1908360 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 0 | Drugs and targets |
1 to 10 of 45
See all 45 drugsTargets31
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| EPOR | Erythropoietin receptor | 4 | Erythropoietin receptor agonist | Phase 1 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 4 | FK506-binding protein 1A inhibitor | Approval | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 3 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 3 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 3 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 2 | Interleukin-2 receptor inhibitor | Approval | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 2 | Interleukin-2 receptor inhibitor | Approval | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 2 | Interleukin-2 receptor inhibitor | Approval | https://conductscience.org/library/genes/3561 | Drugs and targets |
| S1PR1 | Sphingosine 1-phosphate receptor | 2 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/1901 | Drugs and targets |
| S1PR2 | Sphingosine 1-phosphate receptor | 2 | Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | Phase 3 | https://conductscience.org/library/genes/9294 | Drugs and targets |
1 to 10 of 31
See all 31 targetsTrials63
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01120028 | Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy | Phase 2/3 | 852 | 2019-10-01 | Kidney Transplantation | ALEMTUZUMAB, BASILIXIMAB, SIROLIMUS, TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT01843348 | 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients | Phase 3 | 612 | 2017-05-01 | Kidney Transplantation, Renal Transplantation | CYCLOSPORINE, EVEROLIMUS, MYCOPHENOLIC ACID, TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01410448 | Everolimus in de Novo Kidney Transplant Recipients | Phase 3 | 383 | 2017-06-16 | Kidney Transplantation | EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02538107 | An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant | 290 | 2015-11-03 | Anemia, Kidney Transplantation | METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | Its record names the disease | ClinicalTrials.gov | |
| NCT00807144 | Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation | Phase 4 | 102 | 2021-08-27 | End-stage Renal Failure, Graft Rejection | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03020589 | Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients | Phase 4 | 97 | 2022-07-21 | Renal Transplant | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01962922 | Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily. | Phase 3 | 50 | 2016-08-15 | Renal Failure | TACROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03511560 | Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation | Phase 4 | 50 | 2024-07-17 | Renal Transplant Rejection, Kidney Transplant Failure and Rejection | TACROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03611621 | A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation | 31 | 2025-02-07 | Kidney Transplant Failure and Rejection | IMLIFIDASE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03289650 | Extended Release Tacrolimus vs. Twice-Daily Tacrolimus | Phase 3 | 29 | 2023-04-10 | End Stage Renal Disease, Rejection of Renal Transplant | TACROLIMUS ANHYDROUS | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 63
See all 63 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Period 1: Campath 1H/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Serious Infection (at 6-months After Randomization to Induction Therapy) | 135 of 426 | 136 of 426 | 852 | NCT01120028 | Trial comparisons |
| Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Graft Failure (at 6-months After Randomization to Induction Therapy) | 16 of 426 | 13 of 426 | 852 | NCT01120028 | Trial comparisons |
| Period 1: Alemtuzumab/Tacrolimus vs Period 1: Basiliximab/Tacrolimus: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy | 31 of 426 | 68 of 426 | 852 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Major Vascular Event (at 18-months After Randomization to Maintenance Therapy) | 10 of 197 | 13 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Serious Infection (at 18-months After Randomization to Maintenance Therapy) | 95 of 197 | 70 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Cancer (at 18-months After Randomization to Maintenance Therapy) | 17 of 197 | 17 of 197 | 394 | NCT01120028 | Trial comparisons |
| Period 2: Sirolimus vs Period 2: Tacrolimus: Number of Participants With Graft Failure (at 18-Months After Randomization to Maintenance Therapy) | 8 of 197 | 4 of 197 | 394 | NCT01120028 | Trial comparisons |
| Immediate Everolimus (IE) vs Delayed Everolimus (DE): serious adverse events | 73 of 193 | 61 of 190 | 383 | NCT01410448 | Trial comparisons |
| Extended Release Tacrolimus vs Standard Release Tacrolimus: deaths from any cause | 4 of 52 | 2 of 50 | 102 | NCT00807144 | Trial comparisons |
| Extended Release Tacrolimus vs Standard Release Tacrolimus: serious adverse events | 0 of 52 | 1 of 50 | 102 | NCT00807144 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials21
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0010134
GET https://conductscience.org/api/diseases/v1/EFO_0010134/drugs?page=2